ACT II Global Acquisition Corp. (ACTT), which was scheduled to hold their general shareholder vote and special warrant holder vote today to complete their combination with Flavors Holdings Inc. and subsidiaries Merisant Company and MAFCO Worldwide LLC, announced this morning that they have adjourned their meeting and rescheduled for Wednesday, June 24th, to allow for more time to solicit additional proxies from its shareholders and public warrant holders.
As a result of the adjournment, the redemption deadline has been changed as well. The final date for public shareholders to demand redemption of their shares has been extended to 5:00 p.m., Eastern Time, on June 22, 2020. However, the record date remains the same, which is the close of business on May 1, 2020.
This is the first time ACTT has had to adjourn their shareholder meeting. This will give the ACTT team time to strengthen the vote.
AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...
At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...